Skip to main content

AYTU BIOPHARMA, INC

For the period ended Sep 22, 2026. Filed Sep 22, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Sep 22, 2026 · Filed Sep 22, 2026

Use the contents to explore the available documents and sections.

AYTU$1.83+1.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · (in thousands, except share data)

(in thousands, except share data)

June 30,
20262025
ASSETS
Current assets:
Cash and cash equivalents$26,308$30,952
Accounts receivable, net22,77931,155
Inventories6,86011,434
Prepaid expenses and other current assets5,8145,638
Total current assets61,76179,179
Non-current assets:
Property and equipment, net385532
Operating lease right-of-use assets8571,061
Intangible assets, net41,40342,201
Other non-current assets6011,204
Total non-current assets43,24644,998
Total assets$105,007$124,177
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$11,284$10,601
Accrued liabilities35,20538,164
Revolving credit facility6,0749,063
Current portion of debt1,8571,857
Other current liabilities2393,379
Total current liabilities54,65963,064
Non-current liabilities:
Debt, net of current portion9,10110,895
Derivative warrant liabilities1,19926,334
Other non-current liabilities4,7744,918
Total non-current liabilities15,07442,147
Stockholders’ equity:
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding——
Common stock, par value $.0001; 200,000,000 shares authorized; 10,728,208 and 8,976,913 shares issued and outstanding, respectively11
Additional paid-in capital383,060352,500
Accumulated deficit(347,787)(333,535)
Total stockholders’ equity35,27418,966
Total liabilities and stockholders’ equity$105,007$124,177
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.